Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Participants with no evidence of disease activity-3 (NEDA-3)_Core Part

Participants with no evidence of disease activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6-month confirmed disability progression (6mCDP) and new/enlarging T2 lesions on MRI

Time frame: Baseline up to month 24

Number of adverse events (AEs) and serious adverse events (SAEs)_Core Part

Adverse events will be collected throughout the trial. Any safety assessment findings such as laboratory, vital signs, electrocardiogram data that are considered clinically significant or meet the protocol definition of an adverse event will be reported as adverse event or serious adverse event, as appropriate

Time frame: Baseline up to month 24

Annualized rate of new or enlarging T2 lesions_Extension Part

Number of new/enlarging T2 lesions per year on MRI

Time frame: Month 24 up to month 48

Participants with no evidence of disease activity-3 (NEDA-3)_Extension Part

Participants with no evidence of disease activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6-month confirmed disability progression (6mCDP) and new/enlarging T2 lesions on MRI

Time frame: Month 24 up to month 48

Number of Adverse events and serious adverse events_Extension Part

Adverse events will be collected throughout the trial. Any safety assessment findings such as laboratory, vital signs, electrocardiogram data that are considered clinically significant or meet the protocol definition of an adverse event will be reported as adverse event or serious adverse event, as appropriate